Replies to post #26701 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

Opportunity, I know you do not like me posting on this board but here is your answer.

Moro could in fact submit a 510k for approval to monitor colon cancer but first, he would be required to rund some FDA approved clinical trials to prove in fact that DR70 was in fact a predicate for RECAF. DR70 is approved for serial monitoring. That is just not a single one time test so the trials would not just simple one time tests.

To monitor colon cancer, multiple DR70 tests are given over a period of time looking for an increase in the level of Fibrin degradation products.

Until Moro decides to run any trials, there can be no submission of a 510k.

Now, lets examine DR70 or Onko Sure as it is now called. It has been approved to monitor colon cancer for two years and in that time, it has not been able to develop any market at all for the stated use. In fact, RPC has stated in filings that the sales in the US are not significant at all and they indicate their intentions to do no marketing in the US.

You speak of the large increase in the stock price of RPC. The huge increase in the share price was sparked by their announcement of a collaboration to develop their CIT technology. In their filings, they state that a lawsuit was filed in 2004 by Accuvector stating they still owned the patent. If you look at the patent, RPC was forced by a Canadian court to make an assignment of the patent back to Accuvector. That assignment was followed by an assignment of any interest that remained with Dr. Chang to RPC. The net result is that if Dr. Chang indeed had no interest remaining after his initial license to Accuvector, then RPC would have nothing but a lawsuit agianst Dr. Chang. No legitimate company would even attempt to develop the technology with the current patent status.

Now as for the current collaboration in India for the CIT technology, it is by a Indian citizen that was the CEO of a corporation that went out of business in 2008. There is no information on what Gaur Diagno is doing nor the other company he has called Jaiva Technologies. I truly suspect that nothing will ever come of any development of the technology. RPC just needed a pump and they got it.

[Gold Seeker]

Opportunity, if you think that RPC gives "hope" to BioCurex, you are mistaken.

The recent financing that RPC did was "loan shark" rates where about 60% of the loan went back to the lender for fees and penalties. RPC plans for the lenders to convert their notes when the SEC approved the share registration. The conversion is at 28 cents so RPC will have to keep the stock pump going so the lenders can sell the shares.

The press releases have no substance. No money is recieved, just that the partners "intend" to do something. I think there is almost zero chance that the Indian guy will spend the money to do anything with the CIT technology. If you look at the webpage for Gaur Diagno, it is for the consumption of RPC investors and the owner of the website is a company that is known to host scams for anonymouse companies.

Their next quarterly report is due out Aug 16 and I would guess it will be late because they will not want to disclose any sales numbers before the lenders can sell their converted notes.

RPC is definitely NOT a stock you would want to hold at all. A lot of investors are going to be taken to the cleaners with that one.

[Gold Seeker]

Opportunity, I agree that Moro does a terrible job communicating with shareholders. Maybe it is for the same reason that The Bocx considered any investor in BioCurex a speculator.

What would Burger say in a conference call? He would have to admit that Dog RECAF was not selling and that is totally contrary to what Moro had been telling investors. He has always claimed that RECAF would basically sell like hotcakes. If Burger opened the call up to investors, someone is going to ask why Abbott is NOT back on board like Burger stated.

What is Moro going to do? He certainly cannot spend money to develop a Vet POC test. With no sales of Dog RECAF, that would really be tossing money out the door. Money has to indeed be a prime concern to Moro. What he got in the public offering has to last. Moro needs to get the stock price up to force the warrant conversion but Smithline is sitting there with 4 million plus shares to sell when the stock price gets above 14 cents.

Moro has to do something but I have no idea what he can do. I am sure he anticipated Dog RECAF sales would push the stock up to convert the warrants but that is now out the door.

[Gold Seeker]

Opportunity, your approach to this stock does seem more reasonable that some others on this board that just accept whatever they are told by the management. Most also do not understand why I post on this board and also now post on the RPC board. I just do not like for investors to be told a lot of hype that has not substance. Moro has made a lot of claims about RECAF and indeed, at one time I believed what he said.

When Abbott bailed, I soon realized that much of what I thought I knew and had researched about RECAF was solely based on what Moro was stating and writing in journals. Once I got past that point, I found little support for the use of any universal cancer marker. The fact that Dog RECAF is not selling is proving my thoughts about RECAF are true.

[gaboy47]

Opportunity I too share your frustrations. I looked at my history recently regarding my purchases of Biocurex shares. I'm surprised to find out the first block of shares I purchases 04/05/04 I actually sold for a 35% profit. I then purchased more shares 2 days later at $3.14/share, which I still own.

I've been very discouraged recently with the current share price and I too thought it sure would be nice to get some sort of news about any recent progress. How much impact would snippets of news have on the current share price. IMO, if the share price did move up any, the share price would only drift back down in a few days as has been the case in the past.

I'm of the opinion until Biocurex has a steady revenue stream, signs another license agreement or gets a positive update from Inverness, the share price will hoover in the current range. I prefer a significant press release that would move the share price up significantly and keep it there. Based on Dr. Burger's presentation I suspect the next news we hear will involve another license agreement.

Of course by Gold's definition that would only be a pump. By his definition the announcements of the Abbott and Inverness license agreements were pumps as well.

If you look at Gold's past post he claimed the following, might I add and posted several times:

1.) Abbott would return their license, which they haven't
2.) Inverness would return their licnese which they haven't
3.) Biocurex would close the doors, which they haven't
4.) Smithline would receive all rights to Recaf which they haven't
5.) Gold is already telling people Dr. Moro will blow through the money raised during the public offering even though they have enough money to last 3 years

If you recall Dr. Moro once stated on the Agoracom message board he would not release any fluff press releases he would only release news as it materialized. What if Dr. Moro did communicate
they were in talks regarding another license agreement and the deal feel through? What sort of impact would that have on the share price of Biocurex? Even though RPC went from .20/share to 2.59/share, this past Friday the share price closed below a dollar.

I too look forward to the next press release which I would like to see within the next three months but more than I press release I would like to see the share price reach a substainable price based on significant news.

I have a challenge for you. List the things you would like Dr. Moro to update and then ask yourself how much an answer would move the share price and for how long. For the most part historically news only moved the share price for a few days.